Doravirine, Lamivudine and Tenofovir disoproxil fumarate (delstrigo) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review
Doravirine (pifeltro) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search for clinical information on drugs
Technology Briefings Doravirine-islatravir for previously untreated HIV-1 infection 28 JANUARY 2025 Doravirine-islatravir for previously untreated HIV-1 infection Doravirine-islatravir is in development for the treatment of human immunodeficiency virus 1 (HIV-1) in people who have not received previous treatment (treatment naïve). HIV-1 is a virus that attacks the cells of the immune system typically consist of multiple oral tablets, which can be complex and associated with poor treatment adherence. Download PDFRelated postsPreviousNext TECHNOLOGY BRIEFINGS Doravirine-islatravir for managing HIV-1 infection in people who are virally suppressed on antiretroviral therapy JANUARY 2025 TECHNOLOGY BRIEFINGS Doravirine-islatravir for managing HIV-1 infection in virologically supressed patients
Technology Briefings Doravirine-islatravir for managing HIV-1 infection in people who are virally suppressed on antiretroviral therapy 28 JANUARY 2025 Doravirine-islatravir for managing HIV-1 infection in people who are virally suppressed on antiretroviral therapy Doravirine-islatravir is in development for the management of patients with human immunodeficiency virus 1 (HIV-1) who have a low TECHNOLOGY BRIEFINGS Doravirine-islatravir for managing HIV-1 infection in virologically supressed patients JANUARY 2025 TECHNOLOGY BRIEFINGS Rezafungin for preventing invasive fungal disease in patients undergoing allogenic blood and bone marrow transplantation JANUARY 2025 TECHNOLOGY BRIEFINGS Baloxavir marboxil for treating influenza in children aged 3 weeks and older NOVEMBER 2024 TECHNOLOGY BRIEFINGS
Technology Briefings Doravirine-islatravir for managing HIV-1 infection in virologically supressed patients 28 JANUARY 2025 Doravirine-islatravir for managing HIV-1 infection in virologically supressed patients Doravirine-islatravir is in clinical development for the management of patients with human immunodeficiency virus 1 (HIV-1) who have a low level of HIV in their body, known as virological
Doravirine/lamivudine/tenofovir disoproxil (HIV infection) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Doravirin/Lamivudin/Tenofovirdisoproxilfumarat (HIV-Infektion bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2022). Please note : This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-49 Doravirine/lamivudine/tenofovir disoproxil fumarate (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-49 Version 1.0 DOR/3TC
Doravirine (HIV infection in adolescents) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Doravirin ( HIV-Infektion bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V ( Version 1.0; Status: 28 July 2022). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-52 Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-52 Version 1.0 Doravirine (HIV infection in adolescents) 28 July 2022 Institute for Quality and Efficiency
doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu
doravirine (Pifeltro) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific areasCOVID-19
Doravirine (Pifeltro) - for the treatment of adults infected with HIV-1 Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu
Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) - HIV Published 8 March 2021 1 Product update SMC2333 doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film-coated tablets (Delstrigo®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults infected with HIV-1 without past or present
Doravirine (Pifeltro) - HIV Published 8 March 2021 1 Product update SMC2332 doravirine 100mg film-coated tablets (Pifeltro®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine (Pifeltro®) is accepted for use within NHSScotland. Indication under review: in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class
Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Doravirin (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English -language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-07 Doravirine (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A19-07 Version 1.0 Doravirine (HIV infection) 11 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details
Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Doravirin/Lamivudin/Tenofovirdisoproxilfumarat (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note : This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-05 Doravirine/lamivudine/tenofovir disoproxil fumarate (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A19-05 Version 1.0 Doravirine/lamivudine/tenofovir
Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes
No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens. Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs ). This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of ≤50 copies/mL and past NNRTI-RAMs. The main outcome was the proportion of participants with virological failure at Week 48 and Week 96. Secondary outcomes evaluated the rate of viral suppression and transient virological blip, RAMs in the case of virological failure
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens. In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs
Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort. Doravirine (DOR) is a novel antiretroviral agent with a favorable resistance profile and high tolerability. However, evidence is limited on DOR among elderly people living with HIV (PLWH) and whether it might modulate
Use of doravirine-based regimens in clinical practice in Europe: a real-life retrospective observational study. We evaluated antiviral effectiveness and safety of doravirine (DOR)-based regimens in people with HIV (PWH) in routine clinical practice. A retrospective, noninterventional study across 16 sites in five European countries [United Kingdom (UK), France, Spain, Belgium, Netherlands
Durability of doravirine/dolutegravir dual combination in a multicentre cohort of elderly people with HIV. Even though the doravirine/dolutegravir combination is not mentioned by guidelines, real-life data has begun to emerge on its use. We aimed to describe the durability of doravirine/dolutegravir in a multicentre Italian cohort of elderly people with HIV (EPWH). We included all EPWH who ever started the doravirine/dolutegravir combination in six Italian centres and were followed up until treatment discontinuation (TD) for any reason (virological failure, death, treatment interruption for other reasons) on 31 March 2024. Descriptive statistics were used to describe the study population; Kaplan-Meier curves and Cox regression analyses were used to estimate incidence and associated predictors